학술논문
1041TiP - MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2017 28 Supplement 5:v371-v371
Subject
Language
ISSN
0923-7534